First Propedeutic Department of Internal Medicine, AHEPA University Hospital, Medical School, Aristotle University of Thessaloniki, Greece
First Propedeutic Department of Internal Medicine, AHEPA University Hospital, Medical School, Aristotle University of Thessaloniki, Greece.
Postgrad Med J. 2021 Jun;97(1148):380-383. doi: 10.1136/postgradmedj-2020-138756. Epub 2020 Sep 10.
HbA1c is a biomarker with a central role in the diagnosis and follow-up of patients with diabetes, although not a perfect one. Common comorbidities encountered in patients with diabetes mellitus, such as renal insufficiency, high output states (iron deficiency anaemia, haemolytic anaemia, haemoglobinopathies and pregnancy) and intake of specific drugs could compromise the sensitivity and specificity of the biomarker. COVID-19 pandemic poses a pressing challenge for the diabetic population, since maintaining optimal blood glucose control is key to reduce morbidity and mortality rates. Alternative methods for diabetes management, such as fructosamine, glycosylated albumin and device-based continuous glucose monitoring, are discussed.
糖化血红蛋白（HbA1c）是糖尿病患者诊断和随访中的一个重要生物标志物，但并非完美的标志物。在糖尿病患者中常见的合并症，如肾功能不全、高输出状态（缺铁性贫血、溶血性贫血、血红蛋白病和妊娠）和特定药物的摄入，可能会影响生物标志物的敏感性和特异性。COVID-19 大流行对糖尿病患者构成了紧迫的挑战，因为维持最佳血糖控制是降低发病率和死亡率的关键。文中还讨论了糖尿病管理的替代方法，如果糖胺、糖化白蛋白和基于设备的连续血糖监测。
